Sep 12, 2023 7:30 am EDT MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
Aug 3, 2023 4:01 pm EDT MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
Aug 3, 2023 7:30 am EDT MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
Jul 31, 2023 8:30 am EDT MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
Jun 22, 2023 8:30 am EDT MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023 8:30 am EDT MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day